Navigation Links
Luoxin Announces 2008 Third Quarterly Results; Profit Attributable to Shareholders Surged 62.9% to Approximately RMB 138,141,000
Date:10/28/2008

Obtained Shareholders' Approval on the Proposed Transfer of Listing of its

H Shares from GEM to the Main Board

HONG KONG, Oct. 28 /Xinhua-PRNewswire/ -- Shandong Luoxin Pharmacy Stock Co., Ltd. (HKEx: 8058), announced its third quarterly results for the nine months ended 30 September 2008, recording a strong growth in turnover and profit attributable to shareholders.

The Company's turnover rose 36.9% year-on-year to approximately RMB480,155,000, while gross profit increased by 45.6% to approximately RMB237,382,000. Profit attributable to shareholders surged by 62.9% to approximately RMB138,141,000. Basic earnings per share were RMB22.66 cents, representing an increase of 62.9% over the corresponding period in 2007.

As at 30 September 2008, the Company obtained a strong balance sheet with sufficient working capital and no debt.

During the period under review, the Company's Technology Center was certified as Province-Class Technology Center and joined forces with Shenyang Pharmacy University by establishing the Shenyang Pharmacy University and Luoxin Pharma post-doctorate workstation, Shenyang Pharmacy University and Luoxin Pharma education and training station, Shenyang Pharmacy University and Luoxin Pharma intern station. This cooperation has not only enhanced the technological advancement of Luoxin Pharma, but also served as a platform for technology interchange and nurture of talents, laying a solid foundation for the Company's future development.

In order to capture the huge market opportunity in the market, the Company's phase three capacity expansion plan has been completed and commenced operation. The production capacity of aseptic raw material and raw material for system-specific medicines has thus increased by 200 each.

Mr. Liu Baoqi, Chairman of Luoxin Pharma said, "The Company has recently obtained the shareholders' approval for the proposed transfer of listing of its H shares from GEM to the Main Board at the EGM and the respective Class Meetings on 24 October 2008. We believe that the listing on the Main Board not only helps further enhancing the profile of the Group and increases the trading liquidity of the Shares of the Company and recognition, but will also be of great benefit to future growth and business development of Luoxin Pharma in the long run."

For further information, please contact:

Porda International (Finance) PR Group

Ms. Kelly Fung

Tel: +852-3150-6763

Ms. Kate Lam

Tel: +852-3150-6738


'/>"/>
SOURCE Shandong Luoxin Pharmacy Stock Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. UCB Announces 2008 UCB Family RA Scholarship Program Recipients
2. QLT announces third quarter results for 2008
3. QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
4. Response Biomedical Announces Insider Participation in Current Financing
5. American National Announces Third Quarter 2008 Results
6. Digestive Care, Inc. Announces the Complete Submission of the NDA for PANCRECARB(R) (pancrelipase)
7. U.S. Preventive Medicine(R) Announces Major Development for The Prevention Plan(TM)
8. Haemonetics Announces Promotion of Brian Concannon to CEO Effective April 2009
9. HLTH Corporation Announces Commencement of Its Tender Offer
10. ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia
11. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology: